{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:07:53Z","timestamp":1785413273451,"version":"3.56.0"},"reference-count":51,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,7,4]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Approximately 10%\u201320% of patients with Kawasaki disease (KD) are resistant to intravenous immunoglobulins (IVIG) and are at increased risk of developing coronary artery aneurysms (CAA). A potential therapeutic role of anakinra (ANK) in refractory KD has been suggested. The aim of this work is to systematically review and critically appraise the available clinical evidence on the use of ANK in the treatment of IVIG-resistant KD, focusing on treatment indications, timing, dosage, efficacy on fever, inflammation, CAA and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was conducted across PubMed, Embase, Web of Science, Cochrane Library, Emcare, Academic Search Premier and Google Scholar from inception to 9 October 2025, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Eligible studies included all study designs reporting outcomes of patients with KD treated with ANK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-two publications (31 identified through database search and one by cross-referencing) describing 81 patients were included. Most reports were single cases or small series, with two early-phase clinical trials. Treatment with ANK was associated with resolution of fever and systemic inflammation in 94.9% of patients. Complete CAA resolution was reported in 32% and stabilisation\/dimensional reduction in 56.3%. No serious safety concerns were identified. However, these findings derive from heterogeneous and low-quality evidence and should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In IVIG-resistant KD, ANK was effective in controlling systemic inflammation, although more data are needed to assess its efficacy on coronary outcomes. While these findings are encouraging in supporting consideration of ANK for refractory KD, larger randomised clinical studies are warranted to define optimal ANK timing of introduction and dosing, and to evaluate its long-term efficacy on cardiac outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420252129435.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-006868","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:35:20Z","timestamp":1785411320000},"page":"e006868","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Anakinra for intravenous immunoglobulin-resistant Kawasaki disease: a systematic literature review"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3710-0569","authenticated-orcid":false,"given":"Caterina","family":"Matucci-Cerinic","sequence":"first","affiliation":[{"name":"UOC Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini, Genova, Italy"},{"name":"DINOGMI, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1105-5640","authenticated-orcid":false,"given":"Alessia","family":"Alunno","sequence":"additional","affiliation":[{"name":"Internal Medicine and Nephrology Division, Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-4781","authenticated-orcid":false,"given":"Jan W","family":"Schoones","sequence":"additional","affiliation":[{"name":"Directorate of Research Policy (formerly Walaeus Library), Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-1916","authenticated-orcid":false,"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[{"name":"UOC Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8939-5763","authenticated-orcid":false,"given":"Isabelle","family":"Kon\u00e9-Paut","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, National Reference Centre for Auto-Inflammatory Diseases and Amyloidosis of Inflammatory Origin (CEREMAIA), Bic\u00eatre Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), University of Paris Saclay Le Kremlin Bic\u00eatre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8118-0848","authenticated-orcid":false,"given":"Perrine","family":"Dusser","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, National Reference Centre for Auto-Inflammatory Diseases and Amyloidosis of Inflammatory Origin (CEREMAIA), Bic\u00eatre Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), University of Paris Saclay Le Kremlin Bic\u00eatre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"2026073004351078000_12.3.e006868.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001295"},{"key":"2026073004351078000_12.3.e006868.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000484"},{"key":"2026073004351078000_12.3.e006868.3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.164.6.1958"},{"key":"2026073004351078000_12.3.e006868.4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/art.41481","article-title":"Phase II open-label study of anakinra in intravenous immunoglobulin-resistant Kawasaki disease","volume":"73","author":"Kon\u00e9-Paut","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026073004351078000_12.3.e006868.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"2026073004351078000_12.3.e006868.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"PubMed Central PMCID","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026073004351078000_12.3.e006868.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026073004351078000_12.3.e006868.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.12.035"},{"key":"2026073004351078000_12.3.e006868.9","doi-asserted-by":"crossref","unstructured":"Perez RA , Martinez JF , Petracca RL , et al . Anakinra as treatment in an infant with refractory kawasaki disease complicated by multiple giant coronary aneurysms. Cardiol Young 2024;34. doi:10.1017\/S1047951124034103","DOI":"10.1017\/S1047951124034103"},{"key":"2026073004351078000_12.3.e006868.10","unstructured":"Vismara SA , Saurenmann T , Hormann S . Incomplete Kawasaki disease in infancy: difficult to diagnose, dangerous to miss. Swiss Med Wkly 2022;638322585."},{"key":"2026073004351078000_12.3.e006868.11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/annrheumdis-2019-eular.5633","article-title":"OP0147 KAWAKINRA: a phase IIa multicenter trial to assess the efficacy and safety of anakinra in patients with intravenous immunoglobulin-resistant Kawasaki disease","volume":"78","author":"Kon\u00e9-Paut","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026073004351078000_12.3.e006868.12","doi-asserted-by":"crossref","first-page":"503988","DOI":"10.1016\/j.anpede.2025.503988","article-title":"Experience with interleukin-1 blockade in refractory Kawasaki disease","volume":"103","author":"Baena-Palomino","year":"2025","journal-title":"Anales de Pediatr\u00eda (English Edition)"},{"key":"2026073004351078000_12.3.e006868.13","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.00195","article-title":"Resolution of giant coronary aneurysms in a child with refractory Kawasaki disease treated with anakinra","volume":"8","author":"Gambacorta","year":"2020","journal-title":"Front Pediatr"},{"key":"2026073004351078000_12.3.e006868.14","first-page":"647564863","article-title":"Treatment of refractory Kawasaki disease utilizing anakinra in a pediatric patient: a case report","volume":"82","author":"Kain","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"2026073004351078000_12.3.e006868.15","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-229708","article-title":"High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant","volume":"12","author":"Lind-Holst","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2026073004351078000_12.3.e006868.16","article-title":"Complete regression of giant aneurysms in an infant with delayed diagnosis and refractory Kawasaki disease via combination anticytokine therapy: case report and review of similar cases","volume":"2020","author":"Williams","year":"2020","journal-title":"Case Rep Rheumatol"},{"key":"2026073004351078000_12.3.e006868.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.024"},{"key":"2026073004351078000_12.3.e006868.18","doi-asserted-by":"crossref","unstructured":"Abushhaiwia AA , Sasi S , Addala ME , et al . Bilateral giant coronary artery aneurysms in a 7-month-old infant girl with Kawasaki disease. Pediatric Rheumatology Conference: 29th European Paediatric Rheumatology Congress Rotterdam Netherlands; 2023:642856301. doi:10.1186\/s12969-023-00879-8","DOI":"10.1186\/s12969-023-00879-8"},{"key":"2026073004351078000_12.3.e006868.19","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000814"},{"key":"2026073004351078000_12.3.e006868.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12887-019-1695-0","article-title":"Kawasaki disease in infants less than one year of age: an Italian cohort from a single center","volume":"19","author":"Mastrangelo","year":"2019","journal-title":"BMC Pediatr"},{"key":"2026073004351078000_12.3.e006868.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-019-2028-5","article-title":"Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings","volume":"13","author":"Maggio","year":"2019","journal-title":"J Med Case Rep"},{"key":"2026073004351078000_12.3.e006868.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201658"},{"key":"2026073004351078000_12.3.e006868.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-021-00526-0","article-title":"Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms","volume":"19","author":"Halyabar","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026073004351078000_12.3.e006868.24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/rheumato3040015","article-title":"Kawasaki disease complicated with macrophage activation syndrome: the importance of prompt diagnosis and treatment\u2014three case reports","volume":"3","author":"Corinaldesi","year":"2023","journal-title":"Rheumato"},{"key":"2026073004351078000_12.3.e006868.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-023-00891-y","article-title":"Anakinra and hepatotoxicity in pediatric rheumatology: a case series","volume":"21","author":"Martins","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026073004351078000_12.3.e006868.26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12887-017-0852-6","article-title":"A child with resistant Kawasaki disease successfully treated with anakinra: a case report","volume":"17","author":"S\u00e1nchez-Manubens","year":"2017","journal-title":"BMC Pediatr"},{"key":"2026073004351078000_12.3.e006868.27","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211002593","article-title":"Early anti IL-1 treatment replaces steroids in refractory Kawasaki disease: clinical experience from two case reports","volume":"13","author":"Mastrolia","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026073004351078000_12.3.e006868.28","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1097\/INF.0000000000002810","article-title":"Anakinra and etanercept combination treatment in a child with severe, nonresponsive Kawasaki disease","volume":"39","author":"Walser","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2026073004351078000_12.3.e006868.29","doi-asserted-by":"crossref","unstructured":"Lo JE , Zeft A , Panupattanapong S . Resolution of giant coronary artery aneurysm in Kawasaki disease with long-term anakinra therapy: a case report. Pediatric Rheumatology Conference: 29th European Paediatric Rheumatology Congress Rotterdam Netherlands; 2023:642857062. doi:10.1186\/s12969-023-00879-8","DOI":"10.1186\/s12969-023-00879-8"},{"key":"2026073004351078000_12.3.e006868.30","doi-asserted-by":"crossref","first-page":"38786971","DOI":"10.3390\/jcdd11050149","article-title":"Multiresistant Kawasaki disease in a young infant with giant aneurysms growing fast","volume":"11","author":"Amorim-Figueiredo","year":"2024","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026073004351078000_12.3.e006868.31","doi-asserted-by":"crossref","unstructured":"Pinto ME , Meneghel A , Martini G , et al . Efficacy of anakinra in reducing giant coronary aneurysms in refractory Kawasaki disease: a case report. Pediatric Rheumatology Conference: 26th European Paediatric Rheumatology Congress: Part. doi:10.1186\/s12969-020-00470-5","DOI":"10.1186\/s12969-020-00470-5"},{"key":"2026073004351078000_12.3.e006868.32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/art.40784","article-title":"Monocyte-derived interleukin-1\u03b2 as the driver of S100A12-induced sterile inflammatory activation of human coronary artery endothelial cells: implications for the pathogenesis of Kawasaki disease","volume":"71","author":"Armaroli","year":"2019","journal-title":"Arthritis & Rheumatology"},{"key":"2026073004351078000_12.3.e006868.33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-252643"},{"key":"2026073004351078000_12.3.e006868.34","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.115.307072"},{"key":"2026073004351078000_12.3.e006868.35","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.115.306475"},{"key":"2026073004351078000_12.3.e006868.36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600388"},{"key":"2026073004351078000_12.3.e006868.37","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s10875-022-01301-w","article-title":"An immunological axis involving interleukin-1\u03b2 and leucine-rich-\u03b12-glycoprotein reflects therapeutic response of children with Kawasaki disease: implications from the KAWAKINRA trial","volume":"42","author":"Kessel","year":"2022","journal-title":"J Clin Immunol"},{"key":"2026073004351078000_12.3.e006868.38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5114\/ada.2024.145459","article-title":"Clinical significance of caspase-1 in coronary artery lesions in Kawasaki disease and its mechanism of action on vascular smooth muscle cells","volume":"42","author":"Yang","year":"2025","journal-title":"Postepy Dermatol Alergol"},{"key":"2026073004351078000_12.3.e006868.39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/cei.13314","article-title":"IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis","volume":"198","author":"Gorelik","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"2026073004351078000_12.3.e006868.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.06.011"},{"key":"2026073004351078000_12.3.e006868.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.10.012"},{"key":"2026073004351078000_12.3.e006868.42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4070\/kcj.2010.40.7.334","article-title":"Infliximab treatment for refractory Kawasaki disease in Korean children","volume":"40","author":"Song","year":"2010","journal-title":"Korean Circ J"},{"key":"2026073004351078000_12.3.e006868.43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/INF.0000000000001039","article-title":"Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin","volume":"35","author":"Youn","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2026073004351078000_12.3.e006868.44","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S2352-4642(21)00270-4","article-title":"Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial","volume":"5","author":"Burns","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"2026073004351078000_12.3.e006868.45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18387-7","article-title":"Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial","volume":"8","author":"Mori","year":"2018","journal-title":"Sci Rep"},{"key":"2026073004351078000_12.3.e006868.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62298-9"},{"key":"2026073004351078000_12.3.e006868.47","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00431-024-05437-2","article-title":"Efficacy and safety of infliximab in the treatment of Kawasaki disease: a systematic review and meta-analysis","volume":"183","author":"Wang","year":"2024","journal-title":"Eur J Pediatr"},{"key":"2026073004351078000_12.3.e006868.48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12016-016-8581-4","article-title":"Effect and safety of TNF inhibitors in immunoglobulin-resistant Kawasaki disease: a meta-analysis","volume":"52","author":"Xue","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026073004351078000_12.3.e006868.49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4070\/kcj.2018.0214","article-title":"Infliximab treatment for intravenous immunoglobulin-resistant Kawasaki disease: a multicenter study in Korea","volume":"49","author":"Hur","year":"2019","journal-title":"Korean Circ J"},{"key":"2026073004351078000_12.3.e006868.50","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2023-325639"},{"key":"2026073004351078000_12.3.e006868.51","unstructured":"Kone-Paut I , Toumazi A , Bourmaud A . A comparative clinical trial to assess a standardized escalation dose strategy of interleukin-1 blockade in Kawasaki disease: the ANACOMP trial. Clinical Investigation [Internet], Available: https:\/\/www.openaccessjournals.com\/abstract\/a-comparative-clinical-trial-to-assess-a-standardized-escalation-dose-strategy-of-interleukin1-blockade-in-kawasaki-dise-14258.html"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-006868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:35:29Z","timestamp":1785411329000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-006868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,30]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-006868"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-006868","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}